IPO Year: 2014
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/21/2025 | $65.00 | Outperform | Oppenheimer |
| 5/15/2025 | $55.00 | Buy | BTIG Research |
Topline data from the REVERT IPF trial anticipated in 4Q 2025 Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial of TTI-101 in patients suffering from IPF. Key endpoints include safety and lung function (FVC). TTI-101, is an oral, small molecule inhibitor of STAT3.
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in the Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways, being held Tuesday, May 27, 2025, and the Jefferies Global Healthcare Conference, being held June 3 – 5, 2025, in New York, NY. Details are as follows: Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways Format: Fireside Chat Date: Tuesday, May 27, 2025 Time: 11:30 AM ET Jefferies Global Healthcare Conference Format: Corporate P
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that an abstract will be presented at the American Thoracic Society 2025 Annual Conference, which is being held May 16-21 in San Francisco. The abstract highlights the role of STAT3 as a master regulator of idiopathic pulmonary fibrosis (IPF). In preclinical studies, TTI-101, Tvardi's STAT3 inhibitor, suppressed fibrotic markers which are not addressed with currently approved therapies (nintedanib and pirfenidone). Using single-cell RNA sequencing on lung samples
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
8-K/A - Tvardi Therapeutics, Inc. (0001346830) (Filer)
10-Q - Tvardi Therapeutics, Inc. (0001346830) (Filer)
4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
Oppenheimer initiated coverage of Tvardi Therapeutics with a rating of Outperform and set a new price target of $65.00
BTIG Research initiated coverage of Tvardi Therapeutics with a rating of Buy and set a new price target of $55.00